Medtronic Raises 2027 Forecasts Amid Rising Heart Device Demand

Medtronic has revised its fiscal 2027 financial projections upward, citing robust demand for its heart devices used in complex cardiovascular procedures. The medical technology giant has increased the lower end of its adjusted per-share profit forecast from $5.90 to $5.94, while maintaining the upper limit at $6. The company now anticipates annual organic revenue growth between 7.25% and 7.75%, up from its previous estimate of 6.75% to 7.25%.

Strategic Investments in Heart Technology

In a strategic move to enhance its portfolio, Medtronic announced an $80 million investment in heart-valve repair device maker Pi-Cardia, with an option to acquire the company for $210 million. Additionally, Medtronic has invested $700 million in Cornerstone Robotics, securing distribution rights for a robotic surgical device outside the U.S. Medtronic CEO Geoff Martha highlighted the increasing adoption of robotic surgery in emerging markets, where penetration remains below 1%.

Strong Performance Across Segments

Medtronic's cardiovascular segment reported a significant 19.5% increase in quarterly sales, reaching $3.93 billion. This growth was largely driven by an 88% surge in its pulsed field ablation portfolio, utilized to treat irregular heart rhythms. The company's overall quarterly performance exceeded expectations, with an adjusted per-share profit of $1.45 on revenue of $9.76 billion, surpassing analysts' estimates of $1.39 per share on $9.55 billion in sales, according to LSEG data.

Focus on High-Growth Medical Segments

Medtronic's strategy focuses on high-growth areas within the medical technology sector. CEO Martha emphasized the company's commitment to prioritizing segments with large patient populations and significant potential for expansion. The company's steady cadence of mergers and acquisitions is part of its broader strategy to strengthen its position in key markets.

Despite receiving tariff refunds that nearly offset duties paid during the quarter, Medtronic's financial outlook does not factor in potential future refunds, as noted by CFO Thierry Pieton. The company's recent investments and revised forecasts underscore its confidence in sustained growth across its diverse business lines.